非转移性去势抵抗性前列腺癌疾病进展模式及PSA水平与进展风险的关系
ARAMIS研究的事后分析评估了达罗他胺治疗非转移性去势抵抗性前列腺癌的疾病进展模式及PSA应答与进展风险的关系。达罗他胺组转移性进展发生率为14%,安慰剂组为29%,且达罗他胺组达到PSA<0.2 ng/ml的患者放射学进展更少。约30%的转移事件未伴随PSA进展,提示需同时监测影像学和PSA。
要点
- 达罗他胺组转移性进展14%,安慰剂组29%,模式以骨或淋巴结孤立转移为主。
- 达罗他胺组25.1%达到PSA<0.2 ng/ml,安慰剂组仅0.5%。
- 达到PSA<0.2 ng/ml者24个月放射学进展8.7% vs 33%,36个月8.7% vs 50%。
核心结论
- 达罗他胺联合ADT较安慰剂联合ADT降低转移进展风险并改善总生存,且24个月内不改变疾病进展模式。
- 约30%的转移事件未伴随PSA进展,达罗他胺组中PSA<0.2 ng/ml与放射学进展减少相关且随时间维持。
研究设计与样本
- ARAMIS研究的事后分析,患者按2:1随机接受达罗他胺(n=955)或安慰剂(n=554),均联合雄激素剥夺治疗(ADT)。
主要发现
- 转移性进展在达罗他胺组为14%,安慰剂组为29%,转移模式多局限于骨(46%;39%)或淋巴结(32%;40%)。
- 12个月时,达罗他胺组 vs 安慰剂组单纯PSA进展为7.8% vs 35.9%,PSA和放射学同时进展为5.4% vs 21.4%。
- 无PSA进展的放射学进展占达罗他胺组转移事件的35%,占安慰剂组的23%。
- 达罗他胺组25.1%达到PSA<0.2 ng/ml,安慰剂组0.5%;达罗他胺组达到PSA<0.2 ng/ml者24个月放射学进展8.7% vs 33%,36个月8.7% vs 50%。
临床怎么用
- 在nmCRPC患者中,应同时监测影像学和PSA以识别疾病进展,因部分转移事件不伴随PSA进展。
- 达罗他胺治疗中达到PSA<0.2 ng/ml与放射学进展风险降低相关,可作为疗效监测指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In ARAMIS, darolutamide statistically significantly prolonged metastasis-free survival by 2 years and reduced the risk of death by 31% in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We report post hoc analyses of ARAMIS evaluating patterns of disease progression overall and by prostate-specific antigen (PSA) response. METHODS: Patients were randomized 2:1 to darolutamide (n = 955) or placebo (n = 554), with androgen-deprivation therapy (ADT). Progression included metastases on conventional imaging, PSA progression based on Prostate Cancer Working Group 2 criteria or any rise in PSA, and pain progression. Radiological progression was compared between patients who reached undetectable PSA < 0.2 ng/ml at any time and those who did not. RESULTS: Metastatic progression occurred in 14% of patients receiving darolutamide versus 29% of patients receiving placebo, with a consistent pattern mostly isolated to bone (46%; 39%) or lymph nodes (32%; 40%). At 12 months, fewer patients receiving darolutamide versus placebo had PSA progression alone (7.8% vs. 35.9%) or both PSA and radiological progression (5.4% vs. 21.4%). Radiological progression without PSA progression occurred in 35% of metastatic events in the darolutamide group and 23% of metastatic events in the placebo group. Darolutamide led to deep PSA response (< 0.2 ng/ml) versus placebo (25.1% vs. 0.5%), and patients receiving darolutamide who reached PSA < 0.2 ng/ml experienced less radiological progression than those who did not (24 months: 8.7% vs. 33%; 36 months: 8.7% vs. 50%). CONCLUSIONS: Darolutamide plus ADT reduced the risk of metastatic progression and improved overall survival versus placebo plus ADT without changing patterns of disease progression through Month 24. Metastasis occurred without PSA progression in approximately 30% of metastatic events overall. Undetectable PSA with darolutamide was associated with reduced radiological progression that was maintained over time. These results highlight the importance of both imaging and PSA monitoring to identify disease progression in patients with nmCRPC.
引用
- Morgans AK, Wallis CJD, Halabi S, et al. Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2026. PMID: 41680329. doi:10.1038/s41391-026-01076-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。